Image Place holder

Mayer Fishman, MD, PhD


Specialty: Medical Oncology
Program: Genitourinary Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Mayer Fishman is a medical oncologist working in genitourinary oncology and a member of the Chemical Biology and Molecular Medicine program of the immunotherapy and experimental therapeutics programs at Moffitt Cancer Center. He is also a professor in the Departments of Oncologic Sciences and of Internal Medicine at the University of South Florida Morsani College of Medicine. Dr. Fishman is a principal investigator on numerous clinical trials for genitourinary cancer and has a special interest in immune treatment of genitourinary cancers, and particularly in kidney and testis cancer treatment. He is widely published in physician peer-reviewed journals, including Clinical Cancer Research, Lancet Oncology, Journal of Clinical Oncology and PLoS. He is also a former member of the NCCN kidney-testis cancer committee. After medical school at the University of Maryland, where he also received a Ph.D. in biochemistry, Dr. Fishman completed residency in Internal Medicine at Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis, Missouri. He completed a three-year fellowship in Medical Oncology and Hematology at Moffitt Cancer Center, and has been on the faculty at Moffitt Cancer Center for 15 years. He is board certified in internal medicine, medical oncology.  

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • Moffitt Cancer Center - Medical Oncology and Hematology

Residency:

  • Barnes-Jewish Hospital - Internal Medicine

Medical School:

  • University of Maryland School of Medicine - MD
Participating Trials

CLINICAL TRIAL 18345
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Condition: Genitourinary
Intervention: MK-3475 (Keytruda); Ziv-aflibercept
Open

CLINICAL TRIAL 18683
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitenib (INLYTA®) Versus Sunitinub (SUTENT®) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Condition: Genitourinary
Intervention: Avelumab; MSB00100718C (Avelumab); Sunitinib Malate (SU011248); axitinib (AG-013736)
Open

CLINICAL TRIAL 18878
A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received any Chemotherapy for Advanced Disease
Condition: Genitourinary
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); everolimus (RAD001)
Open

CLINICAL TRIAL 18826
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
Condition: Genitourinary
Intervention: ALKS 4230
Open

CLINICAL TRIAL 18536
Coordinated High Dose Interleukin-2 (aldesleukin, Proleukin) and Pembrolizumab (anti-PD1, Keytruda) for Therapy of Metastatic Kidney Cancer
Condition: Genitourinary
Intervention: IL-2 (Interleukin-2); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18492
A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Condition: Genitourinary
Intervention: Seviteronel; VT-464 (Seviteronel)
Open

CLINICAL TRIAL 18509
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable; Placebo
Open

CLINICAL TRIAL 17981
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 17773
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Condition: Genitourinary
Intervention: ASG-22CE
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 18874
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); HBI-8000 (chidamide); Nivolumab
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 18832
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Condition: Multiple
Intervention: Epacadostat; INCB024360 (Epacadostat); INCB039110; INCB050465
Open

CLINICAL TRIAL 18788
A Phase 2 Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18938
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18891
A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types
Condition: Malignant Hematology
Intervention: NKR-2
Open

CLINICAL TRIAL 18885
A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: ODM-201; Placebo; Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 18980
A Phase III, Multicenter, Randomized,Placebo-Controlled, Double-Blind Study of Atezolizumab (AntiPd-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Placebo
Open

CLINICAL TRIAL 18986
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
Condition: Genitourinary
Intervention: AG-014447 (Rucaparib); CO-338 (Rucaparib); PF-01367338-BW (Rucaparib); Rucaparib
Open

CLINICAL TRIAL 18787
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of Instiladrin (rAd-IFN/Syn3)Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer
Condition: Genitourinary
Intervention: INSTILADRIN
Open

CLINICAL TRIAL 19102
A Phase III, Multicenter, Randomized, Placebo-Controlled Study Of Atezolizumab (Anti−PD-L1 Antibody) As Monotherapy And In Combination With Platinum-Based Chemotherapy In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Gemzar (gemcitabine); Paraplatin (carboplatin); carboplatin; cisplatin; gemcitabine
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep;3(9):e172411. Pubmedid: 28817753.
  • Donovan KA, Gonzales BD, Nelson AM, Fishman MN, Zachariah B, Jacobsen PB. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison. Psychooncology. 2017 May. Pubmedid: 28557112.
  • Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Jun;15(6):804-834. Pubmedid: 28596261.
  • Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE. Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Target Oncol. 2017 Jun;12(3):333-340. Pubmedid: 28361451.
  • Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM). Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. Pubmedid: 27916626.
  • Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017 Feb;28(2):254-259. Pubmedid: 27955832.
  • Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Aug. Pubmedid: 28832978.
  • Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B, Jacobsen PB. Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016 Oct;24(10):4159-4166. Pubmedid: 27142516. Pmcid: PMC4995123.
  • Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov;22(22):5461-5471. Pubmedid: 27169994. Pmcid: PMC5106340.
  • Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res. 2016 Nov;22(22):5605-5616. Pubmedid: 27220961. Pmcid: PMC5122466.
  • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov;34(11):1567-1573. Pubmedid: 27072536.
  • Gonzalez BD, Jim HS, Small BJ, Sutton SK, Fishman MN, Zachariah B, Heysek RV, Jacobsen PB. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016 May;24(5):2201-2207. Pubmedid: 26563183. Pmcid: PMC4805468.
  • Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar;34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
  • Poleszczuk J, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, Djeu JY, Finkelstein SE, Enderling H. Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions. Cancer Res. 2016 Mar;76(5):1009-1018. Pubmedid: 26833128.
  • Cessna JM, Jim HS, Sutton SK, Asvat Y, Small BJ, Salsman JM, Zachariah B, Fishman M, Field T, Fernandez H, Perez L, Jacobsen PB. Evaluation of the psychometric properties of the PROMIS Cancer Fatigue Short Form with cancer patients. J Psychosom Res. 2016 Feb;81:9-13. Pubmedid: 26800633. Pmcid: PMC4822706.
  • Rini BI, Tomita Y, Melichar B, Ueda T, Grünwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 Dec;14(6):499-503. Pubmedid: 27236772.
  • Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immun. 2016 Dec;65(12):1533-1544. Pubmedid: 27714434. Pmcid: PMC5099373.
  • Gonzalez BD, Jim HS, Donovan KA, Small BJ, Sutton SK, Park J, Lin HY, Spiess PE, Fishman MN, Jacobsen PB. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. J Urol. 2015 Sep;194(3):690-695. Pubmedid: 25791402. Pmcid: PMC4546512.
  • Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, Park JY, Spiess PE, Fishman MN, Jacobsen PB. Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol. 2015 Jun;33(18):2021-2027. Pubmedid: 25964245. Pmcid: PMC4461804.
  • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):225-230. Pubmedid: 25544725.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug;33(8):339.e17-339.e23. Pubmedid: 26094169.
  • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug;22(4):7882-7889. Pubmedid: 26267026.
  • Fishman MN, Tomshine J, Fulp WJ, Foreman PK. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PLoS One. 2015 Apr;10(4):e0120877. Pubmedid: 25830512. Pmcid: PMC4382117.
  • Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M, Jacobsen PB. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology. 2015 Apr;24(4):472-477. Pubmedid: 24924331. Pmcid: PMC4265307.
  • Fishman M. Challenges facing the development of cancer vaccines. Methods Mol Biol. 2014 Mar;1139:543-553. Pubmedid: 24619703.
  • Cheng P, Kumar V, Liu H, Youn JI, Fishman M, Sherman S, Gabrilovich D. Effects of notch signaling on regulation of myeloid cell differentiation in cancer. Cancer Res. 2014 Jan;74(1):141-152. Pubmedid: 24220241. Pmcid: PMC3886562.
  • Larkin J, Fishman M, Wood L, Negrier S, Olivier K, Pyle L, Gorbunova V, Jonasch E, Andrews L, Staehler M. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol. 2014 Aug;37(4):397-403. Pubmedid: 23357974.
  • Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother. 2014 Apr;37(3):187-191. Pubmedid: 24598453.
  • Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. Eur J Cancer. 2013 Sep;49(13):2841-2850. Pubmedid: 23726267. Pmcid: PMC4666006.
  • Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013 Nov;14(12):1233-1242. Pubmedid: 24140184. Pmcid: PMC4120767.
  • Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar;14(3):211-220. Pubmedid: 23354483. Pmcid: PMC3578019.
  • Jacobsen PB, Phillips KM, Jim HS, Small BJ, Faul LA, Meade CD, Thompson L, Williams CC, Loftus LS, Fishman M, Wilson RW. Effects of self-directed stress management training and home-based exercise on quality of life in cancer patients receiving chemotherapy: a randomized controlled trial. Psychooncology. 2012 Jun;22(6):1229-1235. Pubmedid: 22715124.
  • Fishman MN. Targeted therapy of kidney cancer: keeping the art around the algorithms. Cancer Control. 2013 Jul;20(3):222-232. Pubmedid: 23811706.
  • Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer Control. 2013 Jan;20(1):7-16. Pubmedid: 23302902.
  • McNab P, Quigley B, Mendoza T, Hakam A, Khalil F, Fishman M, Altiok S. The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source. Int J Clin Exp Pathol. 2013 Apr;5(9):982-990. Pubmedid: 23119117. Pmcid: PMC3484497.
  • Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012 Nov;2:169. Pubmedid: 23233905. Pmcid: PMC3515996.
  • Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A. Cellular immunotherapy for soft tissue sarcomas. Immunotherapy. 2012 Mar;4(3):283-290. Pubmedid: 22401634. Pmcid: PMC4501768.
  • Basanta D, Scott JG, Fishman MN, Ayala G, Hayward SW, Anderson AR. Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game. Brit J Cancer. 2012 Jan;106(1):174-181. Pubmedid: 22134510. Pmcid: PMC3251863.
  • Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012 Dec;118(24):6152-6161. Pubmedid: 22692704. Pmcid: PMC4666535.
  • Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 2012 Apr;4(4):373-382. Pubmedid: 22512631. Pmcid: PMC4241355.
  • Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct;17(20):6582-6591. Pubmedid: 21831956. Pmcid: PMC5036398.
  • Gupta S, Carballido E, Fishman M. Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther. 2011 Nov;4:79-96. Pubmedid: 21792315. Pmcid: PMC3143908.
  • Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manag. 2011 May;41(5):859-869. Pubmedid: 21330097. Pmcid: PMC3779914.
  • Fishman M. Review: therapy for kidney cancer with a sarcomatoid component. Clin Adv Hematol Oncol. 2011 Jan;9(1):67-69. Pubmedid: 21326150.
  • Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec;17(24):7765-7775. Pubmedid: 21994418. Pmcid: PMC3972922.
  • Gupta S, Fishman M. Progress and contrasts of the development of tivozanib for therapy of kidney cancer. Expert Opin Pharmacother. 2011 Dec;12(18):2915-2922. Pubmedid: 22098229.
  • Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr;78(1):24-32. Pubmedid: 20399677.
  • Carballido E, Fishman M. Sipuleucel-T: Prototype for development of anti-tumor vaccines. Curr Oncol Rep. 2011 Apr;13(2):112-119. Pubmedid: 21243538.
  • Spiess PE, Fishman MN. Cytoreductive Nephrectomy vs Medical Therapy as Initial Treatment: A Rational Approach to the Sequence Question in Metastatic Renal Cell Carcinoma. Cancer Control. 2010 Oct;17(4):269-278. Pubmedid: 20861814.
  • Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct;33(8):817-827. Pubmedid: 20842055.
  • Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010 Mar;16(6):1812-1823. Pubmedid: 20215551. Pmcid: PMC2840181.
  • Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun;10(6):825-835. Pubmedid: 20553208.
  • Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010 Aug;16(8):880-886. Pubmedid: 20622859. Pmcid: PMC2917488.
  • Love J, Bernard EJ, Cockeram A, Cohen L, Fishman M, Gray J, Morgan D. A multicentre, observational study of sodium picosulfate and magnesium citrate as a precolonoscopy bowel preparation. Can J Gastroenterol. 2009 Oct;23(10):706-710. Pubmedid: 19826647. Pmcid: PMC2776615.
  • Correa JJ, Fishman M, Chuang ST, Spiess PE. Surgery Plus Targeted Therapy for Renal Cell Carcinoma With Isolated Spermatic Cord Metastasis. Clin Genitourin Cancer. 2009 Oct;7(3):E101-E103. Pubmedid: 19815479.
  • Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther. 2009 Dec;9(12):1565-1575. Pubmedid: 19916735.
  • Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 2008 Sep;14(18):5856-5863. Pubmedid: 18794097.
  • Fishman M, Hunter T, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo M, Noyes D, Mahany J, Lee J, Cantor A, Messina J, Seigne J, Pow-Sang J, JanssenW, Antonia S. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. J Immunother (1997). 2008 Jan;31(1):72-80. Pubmedid: 18157014.
  • Nefedova Y, Fishman M, Sherman S, Wang X, Beg A, Gabrilovich D. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007 Nov;67(22):11021-11028. Pubmedid: 18006848.
  • Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.
  • Sullivan P, Mulani P, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007 May;16(4):571-575. Pubmedid: 17294287.
  • Rodriguez A, Fishman M. Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines. Expert Opin Pharmacother. 2007 Dec;8(17):2979-2990. Pubmedid: 18001257.
  • Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 Sep;66(18):9299-9307. Pubmedid: 16982775. Pmcid: PMC1586106.
  • Motzer R, Bolger G, Boston B, Carducci M, Fishman M, Hancock S, HaukeRJ, Hudes G, Jonasch E, Kantoff P, Kuzel T, Lange P, Levine E, Logothetis C, Margolin K, Pohar K, Redman B, Robertson C, Samlowski W, Sheinfeld J. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2006 Nov;4(10):1072-1081. Pubmedid: 17112454.
  • Motzer R, Bolger G, Boston B, Carducci M, Fishman M, Hancock S, HaukeRJ, Hudes G, Jonasch E, Kantoff P, Kuzel T, Lange P, Levine E, Logothetis C, Margolin K, Pohar K, Redman B, Robertson C, Samlowski W, Sheinfeld J. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2006 Nov;4(10):1038-1058. Pubmedid: 17112452.
  • Ryan DP, Appleman LJ, Lynch T, Supko J, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006 Nov;107(10):2482-2489. Pubmedid: 17036355.
  • Cella D, Petrylak DP, Fishman M, Teigland C, Young J, Mulani P. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?. Eur Urol. 2006 May;49(5):781-789. Pubmedid: 16458417.
  • Fishman M, Garrett C, Simon G, Chiappori A, Lush R, Dinwoodie W, Mahany J, Dellaportas A, Cantor A, Gollerki A, Cohen M, Sullivan D. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan;12(2):523-528. Pubmedid: 16428495.
  • Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.
  • Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug;12(15):4645-4651. Pubmedid: 16899614.
  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May;11(9):3335-3341. Pubmedid: 15867232.
  • Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA. Testicular cancer. Clinical practice guidelines. J Natl Compr Canc Ne. 2005 Jan;3(1):52-76. Pubmedid: 19813323.
  • Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Oct;54(4):331-342. Pubmedid: 15148626.
  • Fishman M, Antonia S. Specific antitumour vaccine for renal cancer. Lancet. 2004 Feb;363(9409):583-584. Pubmedid: 14987879.
  • Fishman M, Antonia S. Novel therapies for renal cell carcinoma - an update. Expert Opin Investig Drugs. 2003;12(4):593-609. Pubmedid: 12665415.
  • Fishman M, Antonia S. Cell-based immune therapy for metastatic renal cancer. Expert Rev Anticancer Ther. 2003;3(6):837-849. Pubmedid: 14686706.
  • Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control. 2002;9(4):293-304. Pubmedid: 12228755.
  • Fishman M, Seigne J, Antonia S. Novel therapies for renal cell carcinoma. Expert Opin Investig Drugs. 2001;10(6):1033-1044. Pubmedid: 11772233.
  • Fishman M, Sullivan D. Application of resistance reversal agents in hematologic malignancies; malignancy; current clinical practice. Hematology. 2000;5(5):343-358. Pubmedid: 11399634.
  • Fishman M, Dalton W. Considerations in the management of myeloma. Oncology (Williston Park). 2000;14(11A):72-81. Pubmedid: 11195422.
  • Fishman MN, Sullivan DM. Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies. Hematology. 2000;5(5):343-358. Pubmedid: 27420926.
  • Romero S, Stanton G, Defelice J, Schreiber F, Rago R, Fishman M. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol. 25(4):284-290. Pubmedid: 17628293.